$LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Carole S. Ben-Maimon
CEO
65
Employees
$2.70
Current Price
$285.02M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 7 | 7 | $382,085.82 | 140,810 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 7 | 7 | $382,085.82 | 140,810 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 7 | 7 | $382,085.82 | 140,810 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 7 | 7 | $382,085.82 | 140,810 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 7 | 7 | $382,085.82 | 140,810 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Hamilton Thomas Edward Director | Purchase | 70,000 | $2.67 | $187,082.00 | View Details |
| Nov 11, 2026 | BEN-MAIMON CAROLE Director | Purchase | 18,050 | $2.77 | $49,953.38 | View Details |
| Nov 11, 2026 | THOMAS FRANK E Director | Purchase | 8,000 | $2.73 | $21,800.00 | View Details |
| Nov 11, 2026 | Truitt Joseph Director | Purchase | 3,500 | $2.80 | $9,791.60 | View Details |
| Nov 11, 2026 | Harlow John B. Jr. President and COO | Purchase | 17,800 | $2.80 | $49,918.32 | View Details |
| Nov 11, 2026 | Celano Michael Chief Financial Officer | Purchase | 18,460 | $2.71 | $49,991.53 | View Details |
| Nov 11, 2026 | Shankar Gopi Chief Development Officer | Purchase | 5,000 | $2.71 | $13,549.00 | View Details |
8 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.35
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.35
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.35
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals